drugset / Trial / NCT01380119

Tuberculosis (TB) Immunotherapy Phase 2 Study

NCT01380119 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase II, randomized, placebo-controlled trial, aimed to seek the therapeutic benefit of V7 in combination with standard of care anti-Tuberculosis (TB) therapy (ATT) among Mycobacterium tuberculosis-infected sputum smear positive subjects. The results will be compared to placebo combined with standard ATT therapy. The trial will consist of one stage with sputum evaluation at months 1 and 2.

Timeline

Start
2011-08
Primary completion
2012-08
Completion
2012-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject V7 Vaccine 10 ug Oral

Indications